We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With Adient (ADNT) Q4 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
The upcoming report from Adient (ADNT - Free Report) is expected to reveal quarterly earnings of $0.52 per share, indicating a decline of 1.9% compared to the year-ago period. Analysts forecast revenues of $3.76 billion, representing an increase of 3% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 8.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Adient metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'Net Sales- Asia' will reach $742.08 million. The estimate indicates a change of -6.3% from the prior-year quarter.
Analysts' assessment points toward 'Net Sales- America' reaching $1.78 billion. The estimate indicates a year-over-year change of -0.8%.
The collective assessment of analysts points to an estimated 'Net Sales- EMEA' of $1.24 billion. The estimate points to a change of +12.7% from the year-ago quarter.
The consensus estimate for 'Adjusted EBITDA- Americas' stands at $93.48 million. Compared to the current estimate, the company reported $117 million in the same quarter of the previous year.
Based on the collective assessment of analysts, 'Adjusted EBITDA- Asia' should arrive at $102.23 million. The estimate compares to the year-ago value of $100 million.
Analysts forecast 'Adjusted EBITDA- EMEA' to reach $44.28 million. Compared to the current estimate, the company reported $34 million in the same quarter of the previous year.
Over the past month, shares of Adient have returned -3% versus the Zacks S&P 500 composite's +1.5% change. Currently, ADNT carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stay Ahead of the Game With Adient (ADNT) Q4 Earnings: Wall Street's Insights on Key Metrics
The upcoming report from Adient (ADNT - Free Report) is expected to reveal quarterly earnings of $0.52 per share, indicating a decline of 1.9% compared to the year-ago period. Analysts forecast revenues of $3.76 billion, representing an increase of 3% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 8.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Adient metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'Net Sales- Asia' will reach $742.08 million. The estimate indicates a change of -6.3% from the prior-year quarter.
Analysts' assessment points toward 'Net Sales- America' reaching $1.78 billion. The estimate indicates a year-over-year change of -0.8%.
The collective assessment of analysts points to an estimated 'Net Sales- EMEA' of $1.24 billion. The estimate points to a change of +12.7% from the year-ago quarter.
The consensus estimate for 'Adjusted EBITDA- Americas' stands at $93.48 million. Compared to the current estimate, the company reported $117 million in the same quarter of the previous year.
Based on the collective assessment of analysts, 'Adjusted EBITDA- Asia' should arrive at $102.23 million. The estimate compares to the year-ago value of $100 million.
Analysts forecast 'Adjusted EBITDA- EMEA' to reach $44.28 million. Compared to the current estimate, the company reported $34 million in the same quarter of the previous year.
View all Key Company Metrics for Adient here>>>
Over the past month, shares of Adient have returned -3% versus the Zacks S&P 500 composite's +1.5% change. Currently, ADNT carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>